De novo metastatic breast cancer in patients with a small locoregional tumour (T1-T2/N0): Characteristics and prognosis
- 1 November 2021
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 158, 181-188
Abstract
No abstract availableKeywords
Funding Information
- Daiichi-Sankyo
- Roche
- Eisai
- Meso Scale Diagnostics
- Pfizer
- AstraZeneca
- Les Laboratories Pierre Fabre
This publication has 17 references indexed in Scilit:
- Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse populationCancer Causes & Control, 2016
- Effects of locoregional radiotherapy in patients with metastatic breast cancerThe Breast, 2016
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trialThe Lancet Oncology, 2015
- Impact of locoregional treatment on survival in patients presented with metastatic breast carcinomaThe Breast, 2014
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Meta-Analysis to Determine if Surgical Resection of the Primary Tumour in the Setting of Stage IV Breast Cancer Impacts on SurvivalAnnals of Surgical Oncology, 2013
- Can Locoregional Treatment of the Primary Tumor Improve Outcomes for Women With Stage IV Breast Cancer at Diagnosis?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regressionMedical Oncology, 2012
- Survival differences among women with de novo stage IV and relapsed breast cancerAnnals of Oncology, 2010
- Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer SurvivalAmerican Journal of Epidemiology, 2008